Tharimmune, Inc. (NASDAQ:THAR) (”Tharimmune” or the “Company”), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today ...

Vancouver has fallen short in the first year of its provincially mandated housing targets, but city staff expect the city’s ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Ladies and gentlemen, greetings, and welcome to the Pagaya 3Q ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Good morning, and welcome to the Axsome Therapeutics Third ...

The company now has 87 hospitals, including ambulatory surgical centers, in its pipeline of potential customers who have expressed interest in reviewing its products. Of those, there are 32 ...

Establishing growing body of preclinical data evaluating the DNase-based oncology platform across a number of high-value ...

The agency has placed a partial hold on the phase 2a PORTOLA trial evaluating the selective immunoproteasome inhibitor ...

Writer CEO May Habib explains the four things companies need to know before setting off on their agentic AI journey.

Organizations have already started upgrading from vanilla RAG pipelines to agentic RAG, thanks to the wide availability of large language models with function calling capabilities and new agentic ...

The Chicago Cubs might have the best farm system in baseball heading into next year based on how many future stars they seem ...

With the World Series over and the Arizona Fall League wrapping up, now is a good time to take stock of an exciting year in ...

Submitted New Drug Application (NDA) to FDA for TNX-102 SL for fibromyalgia based on two statistically significant Phase 3 studiesGranted Fast ...